Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genome Diagnostics Laboratory, |
RCV001848584 | SCV002105527 | uncertain significance | Hereditary spastic paraplegia | 2021-10-21 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002543422 | SCV003245451 | uncertain significance | Hereditary spastic paraplegia 39 | 2022-08-16 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 1295 of the PNPLA6 protein (p.Ala1295Thr). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with PNPLA6-related conditions. ClinVar contains an entry for this variant (Variation ID: 1344481). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002543421 | SCV003622142 | uncertain significance | Inborn genetic diseases | 2022-05-09 | criteria provided, single submitter | clinical testing | The c.3883G>A (p.A1295T) alteration is located in exon 34 (coding exon 32) of the PNPLA6 gene. This alteration results from a G to A substitution at nucleotide position 3883, causing the alanine (A) at amino acid position 1295 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |